{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:08:42Z","timestamp":1784549322943,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2025.110985","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:07:47Z","timestamp":1769119667000},"page":"110985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lack of survival benefit of pelvic lymph node dissection for patients with radical prostatectomy and postprostatectomy radiotherapy"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-8100","authenticated-orcid":false,"suffix":"Jr.","given":"Isaac E.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nityam","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"10437","key":"10.1016\/j.urolonc.2025.110985_bib0002","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110985_bib0003","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.110985_bib0004","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"23","key":"10.1016\/j.urolonc.2025.110985_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14235803","article-title":"Pelvic lymphadenectomy may not improve biochemical recurrence-free survival in patients with prostate cancer treated with robot-assisted radical prostatectomy in Japan (The MSUG94 Group)","volume":"14","author":"Namiki","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0006","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000497280","article-title":"Reconsideration on clinical benefit of pelvic lymph node dissection during radical prostatectomy for clinically localized prostate cancer","volume":"103","author":"Fujimoto","year":"2019","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0007","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.110985_bib0008","article-title":"The survival benefit of different lymph node yields in radical prostatectomy for pN1M0 prostate cancer patients: implications from a population-based study","volume":"12","author":"Hu","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0009","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.prnil.2024.01.002","article-title":"Association between pelvic lymph node dissection and survival among patients with prostate cancer treated with radical prostatectomy","volume":"12","author":"Kim","year":"2024","journal-title":"Prostate Int"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO Guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0012","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline. Part III: principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.110985_bib0013","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110985_bib0014","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1590\/s1677-5538.ibju.2020.1063","article-title":"Pelvic lymph node dissection in high-risk prostate cancer","volume":"48","author":"Haiquel","year":"2022","journal-title":"Int Braz J Urol Off J Braz Soc Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12894-023-01228-3","article-title":"The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer","volume":"23","author":"Doan","year":"2023","journal-title":"BMC Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0018","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2024.10.006","article-title":"Pelvic lymph node dissection in prostate cancer: update from a randomized clinical trial of limited versus extended dissection","volume":"87","author":"Touijer","year":"2025","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0019","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/pros.24085","article-title":"Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer","volume":"81","author":"Washington","year":"2021","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.juro.2012.03.129","article-title":"National Comprehensive Cancer Network practice guidelines 2011: need for more accurate recommendations for pelvic lymph node dissection in prostate cancer","volume":"188","author":"Abdollah","year":"2012","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.110985_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10050999","article-title":"Head-to-Head comparison of two nomograms predicting probability of lymph node invasion in prostate cancer and the therapeutic impact of higher nomogram threshold","volume":"10","author":"Venclovas","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110985_bib0022","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.prnil.2024.07.002","article-title":"Comparison of oncological outcomes between extended and no pelvic lymph node dissection in patients with high- or very high-risk prostate cancer: a multi-institutional study","volume":"12","author":"Washino","year":"2024","journal-title":"Prostate Int"},{"issue":"17","key":"10.1016\/j.urolonc.2025.110985_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13174257","article-title":"A review on the current treatment paradigm in high-risk prostate cancer","volume":"13","author":"Burgess","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2025.110985_bib0024","unstructured":"American College of Surgeons. National Cancer Database. [cited 2024 Sept 20]. Available from: https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/."},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0025","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.110985_bib0026","series-title":"Stata statistical software: release 18","year":"2023"},{"key":"10.1016\/j.urolonc.2025.110985_bib0027","unstructured":"Jann B. KMATCH: stata module module for multivariate-distance and propensity-score matching, including entropy balancing, inverse probability weighting, (coarsened) exact matching, and regression adjustment. 2017. Available from: https:\/\/ideas.repec.org\/c\/boc\/bocode\/s458346.html."},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0028","first-page":"20","article-title":"Complications of pelvic lymphadenectomy: do the risks outweigh the benefits?","volume":"12","author":"Loeb","year":"2010","journal-title":"Rev Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.110985_bib0029","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0090-4295(99)80219-2","article-title":"Open pelvic lymph node dissection for prostate cancer: a reassessment","volume":"46","author":"Campbell","year":"1995","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.urolonc.2025.110985_bib0030","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00330-004-2374-5","article-title":"Cost-analysis of staging methods for lymph nodes in patients with prostate cancer: MRI with a lymph node-specific contrast agent compared to pelvic lymph node dissection or CT","volume":"14","author":"H\u00f6vels","year":"2004","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eururo.2007.09.017","article-title":"How many lymphadenectomies does it take to cure one patient?","volume":"53","author":"Klein","year":"2008","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.urolonc.2025.110985_bib0032","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110985_bib0033","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0034","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ucl.2009.11.002","article-title":"Controversies surrounding lymph node dissection for prostate cancer","volume":"37","author":"Palapattu","year":"2010","journal-title":"Urol Clin North Am"},{"issue":"2","key":"10.1016\/j.urolonc.2025.110985_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430466","article-title":"De-escalation of therapy for prostate cancer","volume":"44","author":"Esen","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.urolonc.2025.110985_bib0036","article-title":"Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?","author":"Roberts","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2025.110985_bib0037","article-title":"Identifying the candidates who will benefit from extended pelvic lymph node dissection at radical prostatectomy among patients with prostate cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0038","doi-asserted-by":"crossref","DOI":"10.1111\/and.13157","article-title":"Psychological impact of different primary treatments for prostate cancer: a critical analysis","volume":"51","author":"Maggi","year":"2019","journal-title":"Andrologia"},{"issue":"9","key":"10.1016\/j.urolonc.2025.110985_bib0039","first-page":"288.e1","article-title":"Prostate cancer patients with lymphatic node involvement detected by immunohistochemistry. Is the effort worthwhile?","volume":"42","author":"De Pablos-Rodr\u00edguez","year":"2024","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"1","key":"10.1016\/j.urolonc.2025.110985_bib0040","article-title":"Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.urolonc.2025.110985_bib0041","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2010.10016.x","article-title":"The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer","volume":"108","author":"Schiavina","year":"2011","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2025.110985_bib0042","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.athoracsur.2017.06.066","article-title":"Improved lymph node staging in early-stage lung cancer in the National Cancer Database","volume":"104","author":"Krantz","year":"2017","journal-title":"Ann Thorac Surg"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925005228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:50:57Z","timestamp":1784548257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925005228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143925005228"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110985","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of survival benefit of pelvic lymph node dissection for patients with radical prostatectomy and postprostatectomy radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.110985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110985"}}